Get access

Cardiovascular aspects of psoriasis: an updated review

Authors

  • Aldona Pietrzak MD, PhD,

    1. Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Lublin, Poland
    Search for more papers by this author
  • Joanna Bartosińska MD, PhD,

    1. Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Lublin, Poland
    Search for more papers by this author
  • Graz̊yna Chodorowska MD, PhD,

    1. Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Lublin, Poland
    Search for more papers by this author
  • Jacek C. Szepietowski MD, PhD,

    1. Department of Dermatology, Venereology and Allergology, Medical University, Wroclaw, Poland
    Search for more papers by this author
  • Piotr Paluszkiewicz MD, PhD,

    1. Department of Gastrointestinal Surgery, Lublin Cancer Center, Lublin, Poland
    2. Department of Surgery and Surgical Nursing, Medical University of Lublin, Lublin, Poland
    Search for more papers by this author
  • Robert A. Schwartz MD, MPH

    1. Department of Dermatology, Pathology, Medicine, Pediatrics, Preventive Medicine and Community Health, New Jersey Medical School, Newark, NJ, USA
    Search for more papers by this author

  • Conflicts of interest: none.

  • Funding: DS 168/2011.

Joanna Bartosińska, md, PhD
Department of Dermatology Venereology and Pediatric Dermatology
Medical University of Lublin
20-080 Lublin, Poland
E-mail: jbartosinski@gmail.com

Abstract

Psoriasis, a systemic inflammatory disease, is associated with enhanced atherosclerosis and risk of cardiovascular (CV) disease, which may account for higher morbidity and mortality rates in psoriatic patients. It especially applies to younger psoriatic patients with more severe disease, reducing their life expectancy.

The aim of the study was to review the literature on CV disease in psoriasis as well as the pathogenic mechanisms shared between psoriasis and atherosclerosis. Moreover, case–control and cohort studies published between 2006 and 2011 were selected for meta-analysis. The meta-analysis indicates elevated risk of cardiovascular events in psoriatic patients in relation to non-psoriatic controls (OR 1.28; 95% CI 1.18–1.38).

It is suggested that the treatment of the inflammatory processes involved in the pathogenesis of both psoriasis and atherosclerosis may be beneficial in reducing the CV risk in psoriatic patients. Further in-depth investigations, including prospective studies, are needed to enable more effective management of psoriatic patients in the future.

Get access to the full text of this article

Ancillary